proangiogene

Proangiogenic refers to substances, cells, or processes that promote angiogenesis, the growth of new blood vessels from existing vasculature. This process is essential for normal development, tissue repair, and reproduction, but when unrestrained it can contribute to disease progression, such as in cancer or retinal neovascular disorders.

Key proangiogenic mediators include vascular endothelial growth factor (VEGF) family members, fibroblast growth factors (FGF), angiopoietins, platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), and certain cytokines such as interleukin-8. These factors stimulate endothelial cell proliferation, migration, and survival, facilitating the formation of capillary tubes and the remodeling of the extracellular matrix. Endothelial cells respond to these signals through receptors such as VEGFRs, FGFRs, and the Tie receptors, activating signaling pathways that coordinate vessel sprouting and stabilization.

Regulation of proangiogenic activity is tightly controlled and context-dependent. Hypoxia commonly upregulates proangiogenic signals via hypoxia-inducible factors (HIFs), while inflammatory cells, nitric oxide, and matrix remodeling enzymes contribute to the vascular response. Balance with anti-angiogenic factors determines whether new vessels form.

In clinical contexts, proangiogenic mechanisms are targeted both to suppress tumor growth with anti-angiogenic therapies and to enhance tissue repair and revascularization in ischemic conditions or wound healing. Ongoing research seeks to refine delivery, specificity, and safety of proangiogenic strategies.